Work

Keynote-200 phase 1b: A novel combination study of intravenously delivered coxsackievirus A21 and pembrolizumab in advanced cancer patients.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.tps3108

Authors: Hardev S. Pandha, Christy Ralph, Kevin Harrington, Brendan D. Curti, Rachel E. Sanborn, Wallace L. Akerley, Sumati Gupta, Charles M. Rudin, Jonathan E. Rosenberg, David Ross Kaufman, Emmett V. Schmidt, Mark Grose, Darren Shafren

Institutions: University of Surrey, St James's University Hospital, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Providence Portland Medical Center, Huntsman Cancer Institute, Memorial Sloan Kettering Cancer Center, Merck & Co., Inc., Rahway, NJ, USA (United States), Viralytics Limited (Australia)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2785313752

Cites:

Cited by: 16

Related to: 10